E-钙黏蛋白表达与乳腺癌临床病理学指标相关性的Meta分析

Meta-analysis of the relationship between E-cadherin and clinicopathological indicators in patients with breast cancer

目的:探讨中国乳腺癌患者肿瘤组织中E-钙黏蛋白(E-cadherin)表达与临床病理学指标的相关性。方法:在中国生物医学文献数据库(CBM)、中国知网(CNKI)、Pub Med和Cochrane Library等国内外数据库中搜索有关乳腺癌肿瘤组织中E-cadherin蛋白表达与中国乳腺癌患者临床病理学指标的研究文献,以比值比(OR)及95%可信区间(CI)作为E-cadherin蛋白表达、淋巴结转移、组织学分级、临床分期及受体表达(ER/PR/Her-2)的效应量,采用Review Manager 5.0进行统计学分析。结果:共有32篇文献入选,Meta分析结果显示,E-cadherin在乳腺癌组织中的表达与淋巴结转移[OR=0.27,95%CI(0.18,0.41),P<0.05]、组织学分级[OR=0.50,95%CI(0.33,0.77),P<0.05]、临床分期[OR=0.43,95%CI(0.24,0.76);P<0.05]明显相关。结论:E-cadherin的异常表达与乳腺癌进展及转移密切相关,是乳腺癌患者早期诊断和个体化治疗的潜在分子标志物。

OBJECTIVE：To conduct a Meta-analysis for better understanding the relationship between Ecadherinand clinicopathological indicators in patients with breast cancer. METHODS：All eligible studies reportingassociations between E-cadherin expression and clinicopathological features in breast cancer patients were retrieved fromCBM,CNKI,PubMed and Cochrane Library databases. Review Manager 5.0 was used to calculate the pooled odds ratio（OR） and 95% confidence interval （CI）. RESULTS：A total of 32 studies were included in this Meta-analysis. It wasfound that the expression level of E-cadherin was significantly correlated with lymph node metastasis [OR=0.27,95%CI（0.18,0.41）,P〈0.05],histological grades [OR=0.50,95%CI（0.33,0.77）,P〈0.05],clinical stage [OR=0.43,95%CI（0.24,0.76）,P〈0.05]. CONCLUSION：Aberrant expression of E-cadherin may play an important role in theprogression and metastasis of breast cancer. In addition,aberrent E-cadherin may be a biomarker for early diagnosis andfor development of individual therapy.